Roger Brietbart's laboratory research interests have focused on mechanisms of cardiac gene regulation, and on the application of genomic strategies for identification of novel molecular pathways in the cardiovascular system. From 1996-2002 he headed the cardiovascular drug target discovery programs at Millennium Pharmaceuticals, Inc., in Cambridge, MA. Current research focuses on strategies to identify novel disease genes in congenital heart disease, particularly tetralogy of Fallot, and to elucidate genotype-phenotype correlations.
About Roger Breitbart
Roger Breitbart received his MD from Harvard Medical School. He completed an internship, residency, and fellowship at Children's Hospital Boston.